AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12077006 — intervention group
Group type: COMPARATOR
Intervention: Memory-guided saccades in controls
Number of subjects: 24
Study 9445301 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human IL-5
Number of subjects: 8
Study 9445301 — intervention group
Group type: COMPARATOR
Intervention: Vehicle or 0.4 ng of endotoxin (Control)
Number of subjects: 8
Study 7822813 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) infusion (133 mg/h)
Number of subjects: 18
Study 7822813 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (20 U/kg)
Number of subjects: 18
Study 7822813 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra infusion with endotoxin
Number of subjects: 18
Study 7822813 — intervention group
Group type: COMPARATOR
Intervention: Control study day (no treatment)
Number of subjects: 18
Study 2214478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG (80 mg Tokyo strain) administered at one week intervals for 6 weeks, two week intervals for 12 weeks, and one month intervals for 20 months.
Number of subjects: 44
Study 2214478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment after TUR).
Number of subjects: 44
Study 363345 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (Ng)
Number of subjects: 990
Study 363345 — intervention group
Group type: EXPERIMENTAL
Intervention: Norgestrienone (R2010)
Number of subjects: 990
Study 363345 — intervention group
Group type: COMPARATOR
Intervention: Copper T 200
Number of subjects: 990
Study 31145907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied for 16 minutes to the right posterior superior temporal cortex
Number of subjects: 39
Study 31145907 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 39
Study 31145907 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 39
Study 31145907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 39
Study 28685911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus herbal medicine (two tablets: Tablet 1 with Cinnamomum verum, Glycyrrhiza glabra, Hypericum perforatum, Paeonia lactiflora; Tablet 2 with Tribulus terrestris)
Number of subjects: 122
Study 28685911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus herbal medicine
Number of subjects: 122
Study 26587413 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 75
Study 26587413 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 75
Study 26587413 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 75
Study 23798810 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS‐ABNR repair (group B)
Number of subjects: 16
Study 23798810 — intervention group
Group type: COMPARATOR
Intervention: YDL bladder neck repair (group A)
Number of subjects: 16
Study 21802567 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dark chocolate snack
Number of subjects: 26
Study 21802567 — intervention group
Group type: COMPARATOR
Intervention: Non-chocolate snack
Number of subjects: 26
Study 19015329 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir (1,000/100 mg twice daily) alone for 14 days
Number of subjects: 32
Study 19015329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg once daily)
Number of subjects: 32
Study 19015329 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of saquinavir/ritonavir and ketoconazole
Number of subjects: 32
Study 19015329 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir/ritonavir (1,000/100 mg twice daily) with ketoconazole (200 mg once daily)
Number of subjects: 32
Study 17314111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran
Number of subjects: 518
Study 17314111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 14722170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine infusion of 10 micro g h(‐1) kg(‐1)
Number of subjects: 184
Study 14722170 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hourly intravenous morphine boluses of 30 micro g kg(‐1)
Number of subjects: 184
Study 14722170 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 5 micro g h(‐1) kg(‐1) at birth (term neonates)
Number of subjects: 184
Study 14722170 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 8.5 micro g h(‐1) kg(‐1) at 1 month
Number of subjects: 184
Study 14722170 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 13.5 micro g h(‐1) kg(‐1) at 3 months
Number of subjects: 184
Study 14722170 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 18 micro g h(‐1) kg(‐1) at 1 year
Number of subjects: 184
Study 14722170 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride infusion of 16 micro g h(‐1) kg(‐1) for 1- to 3-yr-old children
Number of subjects: 184
Study 11885871 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg once daily
Number of subjects: 121
Study 11885871 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10-20 mg twice daily
Number of subjects: 121
Study 9554895 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (4 days after surgery with drain in situ)
Number of subjects: 125
Study 8167511 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of alcohol in the form of beer, wine, or spirits with dinner
Number of subjects: 8
Study 3280148 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV) with halothane 1‐1.5% and N2O 66% in O2 (n = 60)
Number of subjects: 120
Study 3280148 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation (IPPV) with halothane 0.5‐1%, N2O 66%, and pancuronium 0.05 mg.kg‐1 (n = 60)
Number of subjects: 120
Study 3280148 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation (SV)
Number of subjects: 120
Study 3280148 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation (IPPV)
Number of subjects: 120
Study 31314073 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with perfect adherence (daily)
Number of subjects: 28
Study 31314073 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with moderate adherence (4 doses/week)
Number of subjects: 28
Study 31314073 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC 300 mg/200 mg with low adherence (2 doses/week)
Number of subjects: 28
Study 31314073 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 30418053 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep surgical site infection (SSI)
Number of subjects: 460
Study 26960416 — intervention group
Group type: EXPERIMENTAL
Intervention: Matured hop extract (MHE) containing 35 mg MHBA, ingested daily for 12 weeks.
Number of subjects: 200
Study 26960416 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage without MHE, ingested daily for 12 weeks.
Number of subjects: 200
Study 25807170 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically harvested radial arteries
Number of subjects: 66
Study 25807170 — intervention group
Group type: COMPARATOR
Intervention: Conventionally harvested radial arteries
Number of subjects: 66
Study 22945605 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component nutrition education intervention
Number of subjects: 8186
Study 22945605 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8186
Study 20145176 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus lapatinib
Number of subjects: 580
Study 20145176 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus placebo
Number of subjects: 580
Study 18984759 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (25 patients)
Number of subjects: 51
Study 18984759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (26 patients)
Number of subjects: 51
Study 15105215 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-frequency auricular electroacupuncture (1 Hz, 2 mA), n = 31
Number of subjects: 61
Study 15105215 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual auricular acupuncture (sham-electroacupuncture), n = 30
Number of subjects: 61
Study 11170151 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (320 mg o.d.)
Number of subjects: 12
Study 11170151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9670433 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 therapy at 2.5 atm abs pressure for 90 min daily for a total of five treatments, starting 1 h after the operation.
Number of subjects: 20
Study 9670433 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 therapy
Number of subjects: 20
Study 9670433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HBO2 therapy)
Number of subjects: 20
Study 8194495 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (ER) group (n = 16)
Number of subjects: 24
Study 2980760 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication M (Monobeltin) - 1,050 mg ASA with enteric coat
Number of subjects: 12
Study 2980760 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication C (Colfarit) - 1,000 mg microencapsulated ASA
Number of subjects: 12
Study 2980760 — intervention group
Group type: COMPARATOR
Intervention: Both medications
Number of subjects: 12
Study 29985380 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-articular oxygen/ozone therapy at a permanent ozone concentration of 8 gr/l (injection area 15-20 sq.cm)
Number of subjects: 89
Study 29985380 — intervention group
Group type: COMPARATOR
Intervention: Generic drug-based treatment alone
Number of subjects: 89
Study 29985380 — intervention group
Group type: EXPERIMENTAL
Intervention: Para-articular oxygen/ozone therapy
Number of subjects: 89
Study 29985380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with oxygen/ozone therapy
Number of subjects: 89
Study 27155232 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day cholecalciferol
Number of subjects: 114
Study 27155232 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU/day cholecalciferol
Number of subjects: 114
Study 27155232 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB treatment (4.3-8.7 J/cm²)
Number of subjects: 114
Study 27155232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral drops and Woods lamp)
Number of subjects: 114
Study 25226912 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 Ncm tightening group
Number of subjects: 30
Study 25226912 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Ncm tightening group
Number of subjects: 30
Study 25226912 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 Ncm tightening group
Number of subjects: 30
Study 23086704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild protocol (FSH 150 IU/day from day 4 followed by GnRH-antagonist from day 8; n=205)
Number of subjects: 412
Study 23086704 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (FSH 150 IU/day; n=207)
Number of subjects: 412
Study 23086704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild protocol
Number of subjects: 412
Study 23086704 — intervention group
Group type: COMPARATOR
Intervention: Long protocol
Number of subjects: 412
Study 20583915 — intervention group
Group type: COMPARATOR
Intervention: Open-flap debridement (OFD)
Number of subjects: 42
Study 20583915 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with collagen membranes
Number of subjects: 42
Study 20583915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with autogenous periosteal membranes and autogenous bone chips (aCPRT)
Number of subjects: 42
Study 18025536 — intervention group
Group type: EXPERIMENTAL
Intervention: ARC1779 (0.05 to 1.0 mg/kg)
Number of subjects: 47
Study 18025536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 16128862 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg day(-1) for 12 weeks
Number of subjects: 18
Study 16128862 — intervention group
Group type: COMPARATOR
Intervention: placebo for 12 weeks
Number of subjects: 18
Study 11292279 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with one or two long (l) 5HTTLPR alleles
Number of subjects: 54
Study 11292279 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with one or two long (l) 5HTTLPR alleles or higher CSF 5HIAA levels
Number of subjects: 54
Study 11292279 — intervention group
Group type: COMPARATOR
Intervention: s/s 5HTTLPR genotype
Number of subjects: 54
Study 9389849 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg i.v.
Number of subjects: 746
Study 9389849 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide 10 mg i.v.
Number of subjects: 746
Study 8719005 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg gemeprost vaginal pessary administered at 6h intervals
Number of subjects: 34
Study 8719005 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthetic
Number of subjects: 34
Study 2906644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% Levobunolol
Number of subjects: 40
Study 2906644 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Timolol
Number of subjects: 40
Study 2906644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 40
Study 2906644 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 40
Study 31223153 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with pharmacy faculty recognized for teaching excellence
Number of subjects: 9
Study 28013352 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 53
Study 28013352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 25970116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PTX 5 mg/kg/hr for 6 hours on 6 successive days
Number of subjects: 120
Study 25970116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23234647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 10 mg
Number of subjects: 0
Study 23234647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 30 mg
Number of subjects: 0
Study 23234647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 50 mg
Number of subjects: 0
Study 23234647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg
Number of subjects: 0
Study 23234647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21817943 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable plate cranioplasty
Number of subjects: 71
Study 21817943 — intervention group
Group type: COMPARATOR
Intervention: Fat graft cranioplasty
Number of subjects: 71
Study 19829036 — intervention group
Group type: EXPERIMENTAL
Intervention: IV midazolam (1 ml)
Number of subjects: 50
Study 19829036 — intervention group
Group type: COMPARATOR
Intervention: No IV midazolam (control group)
Number of subjects: 50
Study 16687909 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanora panoramic radiography
Number of subjects: 96
Study 16687909 — intervention group
Group type: COMPARATOR
Intervention: Bitewing radiography
Number of subjects: 96
Study 15561813 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 200 microg every 2 weeks (Q2W)
Number of subjects: 312
Study 15561813 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 U weekly (QW)
Number of subjects: 312
Study 11753772 — intervention group
Group type: EXPERIMENTAL
Intervention: PPF screw cup
Number of subjects: 80
Study 11753772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedrocel pressfit cup
Number of subjects: 80
Study 11753772 — intervention group
Group type: COMPARATOR
Intervention: Cemented PE cup
Number of subjects: 80
Study 9418619 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion starting at 70 degrees to 100 degrees flexion (Group I)
Number of subjects: 210
Study 9418619 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive motion starting at 0 degrees to 30 degrees flexion (Group II)
Number of subjects: 210
Study 8221741 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril pretreatment (6.25 mg orally 15 min before thrombolysis) in Group A
Number of subjects: 204
Study 8221741 — intervention group
Group type: COMPARATOR
Intervention: Captopril late treatment (administered about 3 days after thrombolysis) in Group B
Number of subjects: 204
Study 8221741 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril pretreatment in Group A
Number of subjects: 204
Study 8221741 — intervention group
Group type: COMPARATOR
Intervention: Captopril late treatment in Group B
Number of subjects: 204
Study 30656782 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Number of subjects: 99
Study 30656782 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Number of subjects: 99
Study 30656782 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis and topical fluoride (control)
Number of subjects: 99
Study 30656782 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous dental appointment restraint
Number of subjects: 99
Study 30656782 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 99
Study 30656782 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous difficult behaviour
Number of subjects: 99
Study 30656782 — intervention group
Group type: EXPERIMENTAL
Intervention: Moment of measurement
Number of subjects: 99
Study 30656782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries on permanent teeth
Number of subjects: 99
Study 29792230 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) support visits
Number of subjects: 172
Study 27269054 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 0
Study 27269054 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV
Number of subjects: 0
Study 27269054 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV + Vitamin A
Number of subjects: 0
Study 27269054 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV only
Number of subjects: 0
Study 27269054 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV + bOPV
Number of subjects: 0
Study 27269054 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 0
Study 24923524 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital video assessment
Number of subjects: 35
Study 24923524 — intervention group
Group type: COMPARATOR
Intervention: Photography assessment
Number of subjects: 35
Study 22072084 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Disease Activity Score (US DAS)
Number of subjects: 90
Study 22072084 — intervention group
Group type: COMPARATOR
Intervention: DAS-28 (standard assessment)
Number of subjects: 90
Study 20449752 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat (31 degrees C + 70% rh)
Number of subjects: 10
Study 20449752 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat + O(3) (31 degrees C + 70% rh + 0.10 ppm O(3))
Number of subjects: 10
Study 20449752 — intervention group
Group type: COMPARATOR
Intervention: Control (20 degrees C + 50% rh)
Number of subjects: 10
Study 20449752 — intervention group
Group type: COMPARATOR
Intervention: Control + O(3) (20 degrees C + 50% rh + 0.10 ppm O(3))
Number of subjects: 10
Study 18756983 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (clopidogrel 75 mg plus aspirin 100 mg)
Number of subjects: 103
Study 18756983 — intervention group
Group type: COMPARATOR
Intervention: Control group (low molecular weight heparin for 7 days plus long-term warfarin)
Number of subjects: 103
Study 18756983 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 16179787 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole for 2 days and 1 hour before the test
Number of subjects: 24
Study 16179787 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 24
Study 12540640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy with calcium disodium EDTA for 3 months followed by repeated therapy weekly for 24 months (32 patients with high-normal body lead burdens).
Number of subjects: 202
Study 12540640 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions for 5 weeks every 6 months (32 control patients).
Number of subjects: 202
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects (n = 289)
Number of subjects: 534
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated individuals
Number of subjects: 534
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of AVP levels
Number of subjects: 534
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with low renin levels (< 10 mU/l; n = 118)
Number of subjects: 534
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving diuretics (n = 39)
Number of subjects: 534
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving beta-blockers (n = 54)
Number of subjects: 534
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving angiotensin-converting enzyme inhibitors (n = 9)
Number of subjects: 534
Study 10100068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving Ca(2+)-antagonists (n = 19)
Number of subjects: 534
Study 8894198 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 406
Study 8894198 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 406
Study 8894198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 2006235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytidine
Number of subjects: 20
Study 2006235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6344611 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 20
Study 6344611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 20
Study 6344611 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 20
Study 6344611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose
Number of subjects: 20